Phase I trial of 4-demethoxydaunorubicin with single i.v. doses.
Sixteen adult patients with a variety of solid tumors entered a phase I trial with 4-demethoxydaunorubicin, a new analogue of daunorubicin. The drug was given as a single i.v. dose of 5-18 mg/m2 repeated every 3-4 weeks. Myelosuppression, especially leucopenia, was dose-limiting. Other toxic effects included mild to moderate nausea and vomiting. The maximum tolerated dose for ambulatory treatment was 18 mg/m2, and 15 mg/m2 every 3-4 weeks is proposed as a starting dose for phase II trials in solid tumors.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001855:Bone Marrow Diseases / Q000139:chemically induced; D003630:Daunorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015255:Idarubicin; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy*
D000970:Antineoplastic Agents; D015255:Idarubicin; D003630:Daunorubicin